Related references
Note: Only part of the references are listed.Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes
T. Heise et al.
DIABETES OBESITY & METABOLISM (2013)
A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes
E. Ferrannini et al.
DIABETES OBESITY & METABOLISM (2013)
Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin
D. Devineni et al.
DIABETES OBESITY & METABOLISM (2012)
Population Pharmacokinetics and Exposure-Response of Albinterferon Alfa-2b
Matthew M. Riggs et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Thiazolidinediones and Risk of Heart Failure in Patients with or at High Risk of Type 2 Diabetes Mellitus A Meta-Analysis and Meta-Regression Analysis of Placebo-Controlled Randomized Clinical Trials
Adrian V. Hernandez et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2011)
Confirmatory analysis for phase III population pharmacokinetics
Chuanpu Hu et al.
PHARMACEUTICAL STATISTICS (2011)
Renal glucose reabsorption inhibitors to treat diabetes
Clifford J. Bailey
TRENDS IN PHARMACOLOGICAL SCIENCES (2011)
Cellular and molecular mechanisms of vascular injury in diabetes - Part I: Pathways of vascular disease in diabetes
Rosalinda Madonna et al.
VASCULAR PHARMACOLOGY (2011)
Type 2 Diabetes: Assessing the Relative Risks and Benefits of Glucose-lowering Medications
Richard M. Bergenstal et al.
AMERICAN JOURNAL OF MEDICINE (2010)
SGLT2 inhibition - a novel strategy for diabetes treatment
Edward C. Chao et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions
Radojka M. Savic et al.
AAPS JOURNAL (2009)
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
James F. List et al.
DIABETES CARE (2009)
Extensions to the Visual Predictive Check to facilitate model performance evaluation
Teun M. Post et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2008)
Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies
Radojka M. Savic et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2007)
Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy
Balaji Agoram et al.
AAPS JOURNAL (2006)
Impact of Diabetes on Vasculature: Focus on Nervous System
Vladimir Skljarevski et al.
CURRENT DIABETES REVIEWS (2005)
Molecular understanding of hyperglycemia's adverse effects for diabetic complications
MJ Sheetz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check
Y Yano et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2001)
A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children
BJ Anderson et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2000)
Share Paper
